SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-230205
Filing Date
2021-07-30
Accepted
2021-07-30 07:57:01
Documents
14
Period of Report
2021-07-29
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d199383d8k.htm   iXBRL 8-K 30675
2 EX-99.1 d199383dex991.htm EX-99.1 18770
6 GRAPHIC g199383g0730012041712.jpg GRAPHIC 3961
  Complete submission text file 0001193125-21-230205.txt   190929

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA xers-20210729.xsd EX-101.SCH 2888
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE xers-20210729_lab.xml EX-101.LAB 18887
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE xers-20210729_pre.xml EX-101.PRE 11857
7 EXTRACTED XBRL INSTANCE DOCUMENT d199383d8k_htm.xml XML 3528
Mailing Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601 844-445-5704
XERIS PHARMACEUTICALS INC (Filer) CIK: 0001346302 (see all company filings)

IRS No.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38536 | Film No.: 211130113
SIC: 2834 Pharmaceutical Preparations